(50 days)
The presence of autoantibodies to a number of nuclear constituents has proven to be useful in the diagnosis of various connective tissue diseases. Although the exact etiology of autoimmune diseases is unknown, and the specific role played by autoantibodies in the onset of various autoimmune connective tissue diseases is obscure, the association and frequency of detection of these antibodies may play a key role in the diagnostic work-up of patients with suspected connective tissue diseases.
The dsDNA ELISA test system is intended for the manual or automated analysis of human serum for the presence or absence of IgG antibodies dsDNA.
Not Found
This is an FDA Premarket Notification (510(k)) K983422 for the Zeus Scientific, Inc. Aptus (Automated) Application for the dsDNA Test System.
Based on the provided text, it is not possible to fully answer all aspects of your request as the document is a regulatory approval letter and does not contain detailed study information. However, I can extract what is available and indicate what information is missing.
Here's a breakdown of the available information and missing details:
1. Table of Acceptance Criteria and Reported Device Performance
This information is not present in the provided document. The letter is an FDA approval for marketing based on substantial equivalence, but it does not detail specific acceptance criteria for a study or numerical performance results.
2. Sample size used for the test set and the data provenance
This information is not present in the provided document.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
This information is not present in the provided document.
4. Adjudication method for the test set
This information is not present in the provided document.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
This information is not present in the provided document. The device is for "manual or automated analysis of human serum for the presence or absence of IgG antibodies dsDNA," suggesting an in-vitro diagnostic, not an imaging device typically associated with MRMC studies or human reader improvement with AI assistance in the way you've described.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
The device is named "Aptus (Automated) Application for the dsDNA ELISA Test System" and states it is intended for "manual or automated analysis." This implies that a standalone, automated performance was considered or is an intended use, but the document does not provide details of such a study.
7. The type of ground truth used
This information is not explicitly stated in the provided document. For a dsDNA ELISA test, the ground truth would typically be established by a reference method or clinical diagnosis of autoimmune disease (e.g., systemic lupus erythematosus), but the document does not specify.
8. The sample size for the training set
This information is not present in the provided document.
9. How the ground truth for the training set was established
This information is not present in the provided document.
Summary of what is known from the document:
- Device Name: Aptus (Automated) Application for the dsDNA ELISA Test System
- Intended Use: The dsDNA ELISA test system is intended for the manual or automated analysis of human serum for the presence or absence of IgG antibodies to dsDNA. It is used in the diagnostic work-up of patients with suspected connective tissue diseases, as the presence of autoantibodies to nuclear constituents has proven useful in diagnosing various connective tissue diseases.
- Regulatory Status: Substantially equivalent to legally marketed predicate devices, classified as Class II, Product Code LRM.
- Type of Device: In-vitro diagnostic device.
To obtain the detailed study information you're asking for, you would typically need to review the 510(k) submission document itself, which would contain the preclinical and clinical study reports. The provided text is only the FDA's decision letter.
{0}------------------------------------------------
Image /page/0/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle or bird-like figure, with its wings spread and head turned to the side.
NOV 1 8 1998
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Mr. Mark J. Kopnitsky Vice President of Research & Development Zeus Scientific, Inc. 200 Evans Way Branchburg, New Jersey 08876
Re: K983422 Aptus (Automated) Application for the dsDNA Test Trade Name: System Regulatory Class: II Product Code: LRM September 28, 1998 Dated: Received: September 29, 1998
Dear Mr. Kopnitsky:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual reqistration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Eederal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{1}------------------------------------------------
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other qeneral information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
510(k) Number (if known): 1993422
Aptus (automated) Application for the dsDNA ELISA Test Device Name: System
Indications for Use:
The presence of autoantibodies to a number of nuclear constituents has proven to be useful in the diagnosis of various connective tissue diseases. Although the exact etiology of autoimmune diseases is unknown, and the specific role played by autoantibodies in the onset of various autoimmune connective tissue diseases is obscure, the association and frequency of detection of these antibodies may play a key role in the diagnostic work-up of patients with suspected connective tissue diseases.
The dsDNA ELISA test system is intended for the manual or automated analysis of human serum for the presence or absence of IgG antibodies dsDNA.
Peter E. Macleod
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use V
OR
Over-The-Counter Use
(Per 21 CFR 801,109)
2-96)
(Optional Format 1-
§ 866.5100 Antinuclear antibody immunological test system.
(a)
Identification. An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues).(b)
Classification. Class II (performance standards).